Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs CarMax, Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while CarMax, Inc trades at $55.75 (market cap $7.91B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock and CarMax, Inc are close in size by market cap, and CarMax, Inc is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | KMX | |
|---|---|---|
Market Cap | $8.04B | $7.91B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $63.53 |
52-Week Low | $241.71 | $30.88 |
Enterprise Value | $7.85B | $26.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
CarMax (KMX) trades at $54.87, up 2.58% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported Q1 2026 earnings that beat expectations, with EPS of $0.34 versus $0.23 expected, driven by cost controls and strategic execution. Revenue for 2025 was $26.35 billion, with net income of $500.56 million, though margins remain thin. Recent news highlights a four-pillar turnaround strategy under new CEO Keith Barr, with insider buying and positive analyst updates supporting sentiment.
The outlook for KMX hinges on successful execution of its growth strategy amid competitive pressures and margin challenges. While technical indicators suggest near-term strength, fundamental risks include high debt levels and fluctuating profitability. Analyst consensus is cautious with a hold-heavy rating, but the stock offers potential for recovery if operational improvements sustain. Investors should weigh the bullish technical setup against fundamental headwinds and ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
